Sensitivity of model-based calculations of red marrow dosimetry to changes in patient-specific parameters

Cancer Biotherapy and Radiopharmaceuticals

Volumn 17, Issue 5, 2002, Pages 535-543

  Stabin, Michael G ^a   Siegel, Jeffry A ^b   Sparks, Richard B ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Nuclear Physics Enterprises   (United States)

^c CDE Dosimetry Services Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; RADIOISOTOPE; YTTRIUM 90;

ARTICLE; BLOOD; BONE; BONE MARROW; BONE MARROW TOXICITY; DOSE CALCULATION; DOSIMETRY; DRUG UPTAKE; HUMAN; ISOTOPE LABELING; MODEL; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY;

BONE AND BONES; BONE DISEASES; BONE MARROW; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; MODELS, BIOLOGICAL; RADIATION DOSAGE; RADIOISOTOPES; RADIOTHERAPY;

EID: 0036028579     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497802760804763     Document Type: Article

References (21)

1. Loevinger R, Budinger T, Watson E. MIRD Primer for Absorbed Dose Calculations, Society of Nuclear Medicine, 1988.
2. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med 1993;34:689-694.
3. Stabin MG, Siegel JA, Sparks RB, Eckerman KF, Breitz HB. Contribution to red marrow absorbed dose from total body activity: A correction to the MIRD method. J Nucl Med 2001;42:492-498.
4. Snyder W, Ford M, Warner G, Watson S. "S," absorbed dose per unit cumulated activity for selected radionuclides and organs, MIRD Pamphlet No. 11, Society of Nuclear Medicine, New York, NY, 1975.
5. Stabin M. MIRDOSE - The personal computer software for use in internal dose assessment in nuclear medicine. J Nucl Med 1996;37:538-546.
6. DeNardo DA, DeNardo GL, O'Donnell RT, Lim S-M, Shen S, Yuan A, DeNardo SJ. Imaging for improved prediction of myelotoxicity after radioimmunotherapy. Cancer 1997;80:2558-2566.
7. Breitz H, Fisher D, Wessels B. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody. J Nucl Med? 1998;39:1746-1751.
8. 131I-labeled anticarcinoembryonic antigen monoclonal antibodies. J Nacl Med 1999;40:1609-1616.
9. Sgouros G, Jureidini IM, Scott AM, Graham MC, Larson SM, Scheinberg DA. Bone marrow dosimetry: Regional variability of marrow-localizing antibody. J Nucl Med 1996;37:695-698.
10. Shen S, DeNardo GL, Sgouros G, O'Donnell RT, DeNardo SJ. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med 1999;40:2102-2106.
11. Eckerman K, Stabin M. Electron absorbed fractions and dose conversion factors for marrow and bone by skeletal regions. Health Phys 2000:78:199-214.
12. International Commission on Radiological Protection. Basic Anatomical and Physiological Data for Use in Radiological Protection: The Skeleton. ICRP Publication 70, 1995.
13. Siegel JA, Lee RA, Pawlyk DA, Horowitz JA, Sharkey RM, Goldenberg DM. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Nucl Med Biol 1989;16:553-559.
14. International Commission on Radiological Protection. Limits for Intakes of Radionuclides by Workers. ICRP Publication 30, Pergamon Press, New York, 1979.
15. Mauch P, Constine L, Greenberger J, Knospe W, Sullivan J, Liesveld J, Deeg H. Hematopoietic stem cell compartment: Acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys 1995;31:1319-1339.
16. Koo K-H, Dussault R, Kaplan P, Kim R, Ahn I-O, Christopher J, Song H-R, Want G-J. Age-related marrow conversion in the proximal metaphysis of the femur: Evaluation with T1-weighted MR imaging. Radiology 1998;206:745-748.
17. Blumenthal RD, Lew W, Juweid M, Alisauskas R, Ying Z, Goldenberg DM. Plasma FLT3-L levels predict bone marrow recovery from myelosuppressive therapy. Cancer 2000;88:333-343.
18. Siegel JA, Yeldell D, Blumenthal RD, Stabin MG, Sparks RB, Sharkey RM, Brenner A, Goldenberg DM. Red marrow radiation dose adjustment using plasma flt3-1 cytokine levels: Improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med, in press, 2002.
19. International Commission on Radiological Protection. Report of the Task Group on Reference Man, ICRP Publication 23, Pergamon Press, New York, NY, 1975.
20. Spiers FW. Beta dosimetry in trabecular bone. In: Delayed Effects of Bone-Seeking Radionuclides (C.W. Mays, ed), University of Utah Press, Salt Lake City, UT, 1969, pp. 95-108.
21. Bouchet LG, Jokisch DW, Bolch WE. A three-dimensional transport model for determining absorbed fractions of energy for electrons within trabecular bone. J Nucl Med 1999;40:1947-1966